{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T13:14:37Z","timestamp":1791983677515,"version":"4.4.0"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To capture the current evidence on therapeutic interventions and prognostic factors in PMR informing a task force of the German, Austrian and Swiss rheumatology societies formulating the updated recommendations for the management of PMR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search of MEDLINE, EMBASE, Cochrane Library, Cinahl and Web of Science was conducted (July 2016\u2013January 2024), supplemented by a search of grey literature. Included were interventional and prognostic studies (both prospective and retrospective) in pure PMR. Risk of bias (ROB) was assessed using Cochrane RoB 2, QUIPS and ROBINS-I tools. Findings were synthesized narratively due to study heterogeneity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 24 publications on 10 interventional trials including one follow-up study, and 13 prognostic studies were included. Evidence from three trials with low ROB in new onset or relapsing patients consistently demonstrated higher remission rates and reduced glucocorticoid (GC) use in patients treated with an IL-6R inhibitor (tocilizumab or sarilumab). Single smaller trials indicated benefit of rituximab and tofacitinib, while MTX showed limited efficacy. Studies on prognostic factors were of variable quality and yielded inconclusive results. Fast-track clinics were associated with improved patient outcomes, including reduced hospitalization and earlier diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>IL6-R inhibitors are effective GC-sparing agents in PMR; rituximab and tofacitinib are also promising. High-quality trials are needed to refine treatment strategies and establish reliable prognostic markers for clinical decision-making.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf418","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T11:37:29Z","timestamp":1754393849000},"page":"6036-6047","source":"Crossref","is-referenced-by-count":6,"title":["Treatment and prognostic factors in PMR: a systematic literature review informing German, Austrian and Swiss guidelines"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6708-0688","authenticated-orcid":false,"given":"Zhivana","family":"Boyadzhieva","sequence":"first","affiliation":[{"name":"Department for Rheumatology and Clinical Immunology, Charit\u00e9 Universit\u00e4tsmedizin Berlin , Berlin,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Reisch","sequence":"additional","affiliation":[{"name":"Department for Rheumatology and Immunology, Medical University of Graz , Graz,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Schneider","sequence":"additional","affiliation":[{"name":"Clinic of Rheumatology and Hiller Resarch Unit, UKD, Heinrich-Heine-University , Duesseldorf,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2534-550X","authenticated-orcid":false,"given":"Frank","family":"Buttgereit","sequence":"additional","affiliation":[{"name":"Department for Rheumatology and Clinical Immunology, Charit\u00e9 Universit\u00e4tsmedizin Berlin , Berlin,","place":["Germany"]},{"name":"Deutsches Rheumaforschungszentrum , Berlin,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0173-0668","authenticated-orcid":false,"given":"Christian","family":"Dejaco","sequence":"additional","affiliation":[{"name":"Department for Rheumatology and Immunology, Medical University of Graz , Graz,","place":["Austria"]},{"name":"Department of Rheumatology, Hospital of Bruneck (ASAA-SABES), Teaching Hospital of the Paracelsus Medical University , Brunico,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"2025120216024801200_keaf418-B1","first-page":"1694","article-title":"Trends in the incidence of polymyalgia rheumatica over a 30 year period in Olmsted County, Minnesota, USA","volume":"29","author":"Doran","year":"2002","journal-title":"J Rheumatol"},{"key":"2025120216024801200_keaf418-B2","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1136\/annrheumdis-2015-207492","article-title":"2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative","volume":"74","author":"Dejaco","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025120216024801200_keaf418-B3","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00393-018-0476-8","article-title":"[S3 guidelines on treatment of polymyalgia rheumatica: evidence-based guidelines of the German Society of Rheumatology (DGRh), the Austrian Society of Rheumatology and Rehabilitation (OGR) and the Swiss Society of Rheumatology (SGT) and participating medical scientific specialist societies and other organizations]","volume":"77","author":"Buttgereit","year":"2018","journal-title":"Z Rheumatol"},{"key":"2025120216024801200_keaf418-B4","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1136\/annrheumdis-2011-200329","article-title":"2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative","volume":"71","author":"Dasgupta","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2025120216024801200_keaf418-B5","doi-asserted-by":"crossref","first-page":"672","DOI":"10.7326\/0003-4819-97-5-672","article-title":"Polymyalgia rheumatica: a 10-year epidemiologic and clinical study","volume":"97","author":"Chuang","year":"1982","journal-title":"Ann Intern Med"},{"key":"2025120216024801200_keaf418-B6","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/0049-0172(84)90012-X","article-title":"Long-term follow-up of polymyalgia rheumatica: evidence for synovitis","volume":"13","author":"Healey","year":"1984","journal-title":"Semin Arthritis Rheum"},{"key":"2025120216024801200_keaf418-B7","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2169\/internalmedicine1962.28.452","article-title":"Clinical studies of polymyalgia rheumatica. A proposal of diagnostic criteria","volume":"28","author":"Nobunaga","year":"1989","journal-title":"Jpn J Med"},{"key":"2025120216024801200_keaf418-B8","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1136\/ard.38.5.434","article-title":"An evaluation of criteria for polymyalgia rheumatica","volume":"38","author":"Bird","year":"1979","journal-title":"Ann Rheum Dis"},{"key":"2025120216024801200_keaf418-B9","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2025120216024801200_keaf418-B10","doi-asserted-by":"crossref","first-page":"427","DOI":"10.7326\/0003-4819-144-6-200603210-00010","article-title":"Evaluation of the quality of prognosis studies in systematic reviews","volume":"144","author":"Hayden","year":"2006","journal-title":"Ann Intern Med"},{"key":"2025120216024801200_keaf418-B11","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"2025120216024801200_keaf418-B12","author":"Jeremy"},{"key":"2025120216024801200_keaf418-B13","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1097\/RHU.0000000000001969","article-title":"Risk factors for relapse and\/or prolonged glucocorticoid therapy in polymyalgia rheumatica: multicenter study in 185 patients","volume":"30","author":"Vinicki","year":"2023","journal-title":"J Clin Rheumatol"},{"key":"2025120216024801200_keaf418-B14","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.3390\/jcm10132948","article-title":"Steroid-sparing effect of tocilizumab and methotrexate in patients with polymyalgia rheumatica: a retrospective cohort study","volume":"10","author":"Izumi","year":"2021","journal-title":"J Clin Med"},{"key":"2025120216024801200_keaf418-B15","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s00296-020-04783-2","article-title":"Effect of add-on methotrexate in polymyalgia rheumatica patients flaring on glucocorticoids tapering: a retrospective study","volume":"41","author":"Marsman","year":"2021","journal-title":"Rheumatol Int"},{"key":"2025120216024801200_keaf418-B16","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1111\/ggi.13460","article-title":"Retrospective analysis of the usefulness of a protocol with high-dose methotrexate in polymyalgia rheumatica: results of a single-center cohort of 100 patients","volume":"18","author":"Quartuccio","year":"2018","journal-title":"Geriatr Gerontol Int"},{"key":"2025120216024801200_keaf418-B17","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1136\/annrheumdis-2021-221126","article-title":"Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2\/3 randomised controlled trial","volume":"81","author":"Bonelli","year":"2022","journal-title":"Ann Rheumat Dis"},{"key":"2025120216024801200_keaf418-B18","first-page":"2196","article-title":"Effect of tocilizumab on disease activity in patients with active polymyalgia rheumatica on glucocorticoid therapy: a randomized clinical trial","volume":"74","author":"Devauchelle","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2025120216024801200_keaf418-B19","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1056\/NEJMoa2303452","article-title":"Sarilumab for relapse of polymyalgia rheumatica during glucocorticoid taper","volume":"389","author":"Spiera","year":"2023","journal-title":"N Engl J Med"},{"key":"2025120216024801200_keaf418-B20","author":"Regeneron","year":"2023"},{"key":"2025120216024801200_keaf418-B21","author":"Kaufman","year":"2024"},{"key":"2025120216024801200_keaf418-B22","doi-asserted-by":"crossref","first-page":"e758","DOI":"10.1016\/S2665-9913(21)00245-9","article-title":"Efficacy of rituximab in patients with polymyalgia rheumatica: a double-blind, randomised, placebo-controlled, proof-of-concept trial","volume":"3","author":"Marsman","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2025120216024801200_keaf418-B23","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S2665-9913(23)00032-2","article-title":"1-year results of treatment with rituximab in polymyalgia rheumatica: an extension study of a randomised double-blind placebo-controlled trial","volume":"5","author":"Bolhuis","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"2025120216024801200_keaf418-B24","doi-asserted-by":"crossref","first-page":"e728","DOI":"10.1016\/S2665-9913(23)00246-1","article-title":"Abatacept in early polymyalgia rheumatica (ALORS): a proof-of-concept, randomised, placebo-controlled, parallel-group trial","volume":"5","author":"Saraux","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"2025120216024801200_keaf418-B25","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.2147\/IJGM.S414267","article-title":"Efficacy of JAK inhibitors versus DMARDs in the treatment of polymyalgia rheumatica in China","volume":"16","author":"Gu","year":"2023","journal-title":"Int J Gen Med"},{"key":"2025120216024801200_keaf418-B26","doi-asserted-by":"crossref","first-page":"e1004249","DOI":"10.1371\/journal.pmed.1004249","article-title":"Efficacy and safety of tofacitinib in patients with polymyalgia rheumatica (EAST PMR): an open-label randomized controlled trial","volume":"20","author":"Ma","year":"2023","journal-title":"PLoS Med"},{"key":"2025120216024801200_keaf418-B27","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s41927-022-00274-y","article-title":"(Dis)agreement of polymyalgia rheumatica relapse criteria, and prediction of relapse in a retrospective cohort","volume":"6","author":"Bolhuis","year":"2022","journal-title":"BMC Rheumatol"},{"key":"2025120216024801200_keaf418-B28","doi-asserted-by":"crossref","first-page":"102692","DOI":"10.1016\/j.autrev.2020.102692","article-title":"Impact of age at diagnosis in polymyalgia rheumatica: a retrospective cohort study of 218 patients","volume":"19","author":"Van Hemelen","year":"2020","journal-title":"Autoimmun Rev"},{"key":"2025120216024801200_keaf418-B29","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1136\/annrheumdis-2017-eular.4033","article-title":"Therapeutic response to prednisone according to the age in polymyalgia rheumatica: a controlled study","volume":"76","author":"Charpentier","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025120216024801200_keaf418-B30","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1007\/s10238-022-00976-0","article-title":"Predictors of complete 24-month remission and flare in patients with polymyalgia rheumatica","volume":"23","author":"Perricone","year":"2023","journal-title":"Clin Exp Med"},{"key":"2025120216024801200_keaf418-B31","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s11739-023-03373-x","article-title":"Clinical, laboratory and ultrasonographic findings at baseline predict long-term outcome of polymyalgia rheumatica: a multicentric retrospective study: polymyalgia rheumatica predicted by ultrasonographic findings polymyalgia rheumatica outcome predicted early by ultrasound","volume":"18","author":"Conticini","year":"2023","journal-title":"Intern Emerg Med"},{"key":"2025120216024801200_keaf418-B32","first-page":"1297","article-title":"Polymyalgia rheumatica patients with and without elevated baseline acute phase reactants: distinct subgroups of polymyalgia rheumatica","volume":"71","author":"Marsman","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025120216024801200_keaf418-B33","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4081\/reumatismo.2021.1395","article-title":"Red cell distribution width is a potential predictor of early relapse in polymyalgia rheumatica","volume":"73","author":"Soddu","year":"2021","journal-title":"Reumatismo"},{"key":"2025120216024801200_keaf418-B34","doi-asserted-by":"crossref","first-page":"1759720X19864822","DOI":"10.1177\/1759720X19864822","article-title":"Thrombocytosis as a prognostic factor in polymyalgia rheumatica: characteristics determined from cluster analysis","volume":"11","author":"Hayashi","year":"2019","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2025120216024801200_keaf418-B35","first-page":"3121","article-title":"Neutrophil to lymphocyte ratio predicts glucocorticoid resistance in polymyalgia rheumatica","volume":"70","author":"Owen","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2025120216024801200_keaf418-B36","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1111\/1756-185X.13978","article-title":"Predictors of glucocorticoid-free remission in patients with polymyalgia rheumatica treated with prednisolone","volume":"23","author":"Hattori","year":"2020","journal-title":"Int J Rheum Dis"},{"key":"2025120216024801200_keaf418-B37","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s41927-021-00210-6","article-title":"The fast-track outpatient clinic significantly decreases hospitalisation rates among polymyalgia rheumatica patients","volume":"5","author":"Chrysidis","year":"2021","journal-title":"BMC Rheumatol"},{"key":"2025120216024801200_keaf418-B38","doi-asserted-by":"crossref","first-page":"105185","DOI":"10.1016\/j.jbspin.2021.105185","article-title":"Fast track clinic for early diagnosis of polymyalgia rheumatica: impact on symptom duration and prednisolone initiation","volume":"88","author":"Fr\u00f8lund","year":"2021","journal-title":"Joint Bone Spine"},{"key":"2025120216024801200_keaf418-B39","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.semarthrit.2021.03.006","article-title":"Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in a randomized trial","volume":"51","author":"Spiera","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"2025120216024801200_keaf418-B40","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1111\/1756-185X.13723","article-title":"Tocilizumab monotherapy for polymyalgia rheumatica: a prospective, single-center, open-label study","volume":"22","author":"Chino","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"2025120216024801200_keaf418-B41","author":"ClinicalTrials.gov","year":"2022"},{"key":"2025120216024801200_keaf418-B42","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/art.40044","article-title":"A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis","volume":"69","author":"Langford","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025120216024801200_keaf418-B43","article-title":"Baricitinib in early polymyalgia rheumatica (BACHELOR Study) [abstract]","volume":"76 (suppl 9)","author":"Saraux","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"2025120216024801200_keaf418-B44","first-page":"624","article-title":"Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study","volume":"23","author":"Ferraccioli","year":"1996","journal-title":"J Rheumatol"},{"key":"2025120216024801200_keaf418-B45","doi-asserted-by":"crossref","first-page":"493","DOI":"10.7326\/0003-4819-141-7-200410050-00005","article-title":"Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial","volume":"141","author":"Caporali","year":"2004","journal-title":"Ann Intern Med"},{"key":"2025120216024801200_keaf418-B46","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1136\/ard.55.4.218","article-title":"Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?","volume":"55","author":"van der Veen","year":"1996","journal-title":"Ann Rheum Dis"},{"key":"2025120216024801200_keaf418-B47","article-title":"Results of a one year randomized double-blind placebo-controlled trial with methotrexate 25 mg per week for recently diagnosed polymyalgia rheumatica [abstract]","volume":"76","author":"Bolhuis","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"2025120216024801200_keaf418-B48","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1136\/annrheumdis-2024-eular.734","article-title":"POS0280 effectiveness of methotrexate and leflunomide as corticoid-sparing drugs in patients with polymyalgia rheumatica","volume":"83","author":"Vinicki","year":"2024","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf418\/63969707\/keaf418.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/12\/6036\/63969707\/keaf418.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/12\/6036\/63969707\/keaf418.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T21:02:57Z","timestamp":1764709377000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/12\/6036\/8223487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":48,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,8,6]]},"published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf418","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,8,6]]}}}